Ming Lei
28Patents
7h-index
89Co-inventors
68Inventor score
Filing activity: Mar 17, 2010 → Jun 21, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10253086B2 | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Chemistry; Metallurgy | 20 | Active |
| US9605080B2 | Antibodies against CD73 | Physics | 19 | Active |
| US9290573B2 | Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies | Chemistry; Metallurgy | 16 | Active |
| US9771562B2 | Method for culture of human and mouse prostate organoids and uses thereof | Chemistry; Metallurgy | 14 | Active |
| US10100129B2 | Antibodies against CD73 and uses thereof | Physics | 13 | Active |
| US10525083B2 | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain | Chemistry; Metallurgy | 9 | Active |
| US8883735B2 | Low density lipoprotein-related protein 6 (LRP6)-half life extender constructs | Emerging Cross-Sectional Technologies | 7 | Active |
| US10653791B2 | Antibodies comprising modified heavy constant regions | Chemistry; Metallurgy | 7 | Active |
| US11149076B2 | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Chemistry; Metallurgy | 5 | Active |
| US11213586B2 | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) | Chemistry; Metallurgy | 4 | Active |
| US10167343B2 | Antibodies against CD73 | Physics | 3 | Active |
| US11026976B2 | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain | Chemistry; Metallurgy | 2 | Active |
| US9173960B2 | Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs | Emerging Cross-Sectional Technologies | 1 | Active |
| US10647902B1 | Temporary plugging agent for drilling fluid and preparation method thereof, and water-based drilling fluid and use thereof | Chemistry; Metallurgy | 0 | Active |
| US11407828B2 | Anti-CLauDiN 18 antibodies and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US12344657B2 | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | Chemistry; Metallurgy | 0 | Active |
| US8970318B2 | Transforming circuit | Electricity | 0 | Active |
| US12365727B2 | Anti-interleukin-23 P19 antibodies and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| USRE47860E1 | Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructs | General | 0 | Active |
| US11098331B2 | Method for producing lysine by utilizing adsorption and immobilized fermentation of recombinant corynebacterium glutamicum | Chemistry; Metallurgy | 0 | Active |
| US11118171B2 | Recombinant corynebacterium glutamicum for producing lysine by biofilm continuous fermentation and construction method thereof | Chemistry; Metallurgy | 0 | Active |
| US11267721B2 | Artificial nacre material with layered structure and preparation method thereof | Chemistry; Metallurgy | 0 | Active |
| US11352440B2 | Antibodies against CD73 and uses thereof | Physics | 0 | Active |
| US11872249B2 | Method of treating cancer by administering immune effector cells expressing a chimeric antigen receptor comprising a CD20 binding domain | Chemistry; Metallurgy | 0 | Active |
| USRE49847E1 | Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain | General | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.